Interferon-alpha in the treatment of essential thrombocythemia

Leukemia & Lymphoma
E LengfelderR Hehlmann

Abstract

Interferon alpha (IFN) inhibits the growth of megakaryocytic progenitors in normal hematopoiesis and in patients with essential thrombocythemia (ET) leading to a reduction of peripheral platelet counts. The effectiveness in the induction therapy of patients with ET is demonstrated in 11 international studies including 212 patients. With an average dose of about 3 mill IU IFN daily, the response rate was about 90%. Further studies investigated the practicability and the success of IFN maintenance therapy. The results show that IFN can effectively control platelet counts over a period of several years. During maintenance the IFN dose could be reduced in the majority of patients. However, sustained unmaintained complete remissions were obtained in only 12% of the patients. Side effects were frequently the limiting factors in treatment with IFN especially in older patients. Analyzing a total of 273 patients, IFN therapy was terminated in 25% against the primary treatment plan. Of the currently effective drugs in controlling the platelet counts in ET, IFN is the only antiproliferative agent with immuno-modulating properties. Thus far, no leukemogenic or significant gonadotoxic effects have been observed. In a subset of the patients ...Continue Reading

References

Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·X YataganasG Vayopoulos
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M GiraltA López-Borrasca
Mar 1, 1991·European Journal of Haematology·L CataniS Tura
Oct 1, 1991·British Journal of Haematology·H GisslingerH Ludwig
Oct 1, 1991·British Journal of Haematology·F J Giles
Oct 1, 1991·Annals of Hematology·S SacchiM F Martelli
Jan 1, 1990·American Journal of Hematology·F E MillardG G Marino
Mar 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S CortelazzoT Barbui
Aug 1, 1990·Cancer·P FenauxF Bauters
Jul 9, 1988·Lancet·F J GilesA B Mehta
Jan 1, 1987·Cancer Immunology, Immunotherapy : CII·H LudwigM Micksche
Dec 1, 1983·Annals of Internal Medicine·M TalpazJ U Gutterman
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
May 1, 1995·British Journal of Haematology·N el KassarB Grandchamp
Jan 1, 1994·Acta Haematologica·V RamettaR Cimino
Jan 1, 1994·Scandinavian Journal of Rheumatology·A J GeirssonL P Asgeirsdóttir
Aug 1, 1993·Annals of Hematology·P J van Genderen, J J Michiels
Oct 1, 1993·Deutsche medizinische Wochenschrift·M GriesshammerH Heimpel

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Tiziano Barbui
Jul 17, 2008·Annals of Hematology·Gunnar Birgegård
May 5, 1999·Critical Reviews in Oncology/hematology·T Barbui, G Finazzi
Nov 23, 2007·The Cancer Journal·Guido Finazzi, Tiziano Barbui
Dec 2, 2006·Drugs·Elisabeth I Penninga, Ole W Bjerrum
May 15, 2013·Expert Opinion on Pharmacotherapy·Gunnar Birgegård
Sep 15, 2015·Expert Review of Hematology·María Luisa AnteloJose María Raya
Mar 19, 2013·La Revue de médecine interne·M Cheminant, R Delarue
Nov 28, 2012·Medicina clínica·Gemma RamirezSylvia Plaza
Jul 13, 2012·Blood Reviews·Tiziano BarbuiGuido Finazzi
Jun 24, 2010·Critical Reviews in Oncology/hematology·Suzita M NoorAlister C Ward
Mar 25, 2010·British Journal of Haematology·Claire N HarrisonUNKNOWN British Committee for Standards in Haematology
Jun 21, 2005·Blood Reviews·Guido Finazzi, Tiziano Barbui
Jan 20, 2000·Baillière's Clinical Haematology·A Tefferi, M N Silverstein
Dec 12, 2002·Hematology·Apostolia-Maria Tsimberidou, Francis J Giles
Oct 8, 2005·Seminars in Hematology·Guido Finazzi, Claire Harrison
May 5, 2001·Expert Opinion on Pharmacotherapy·M GriesshammerM Grünewald
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Naseema Gangat, Ayalew Tefferi
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans Carl HasselbalchRichard T Silver
Dec 25, 2008·Expert Review of Anticancer Therapy·Ashkan Emadi, Jerry L Spivak
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·J J Michiels
Nov 5, 2011·Leukemia·G Finazzi
Aug 31, 2007·European Journal of Haematology. Supplementum·Martin Griesshammer
Feb 1, 2009·Expert Review of Hematology·Alessandro M VannucchiAlberto Bosi
Aug 2, 2012·Birth Defects Research. Part A, Clinical and Molecular Teratology·Brady P SeligJohn J Mulvihill
Feb 5, 2013·Expert Review of Hematology·Richard T SilverHans Carl Hasselbalch
Nov 25, 2003·Hematology·Jerry L SpivakMonia Marchetti
Jan 1, 1997·Hematology·T BarbuiT C Pearson
May 3, 2001·Blood Reviews·D MateiV J Marder

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.